Technological Aspects of Ensuring the Specific Safety of Human Immunoglobulin and Albumin Preparations


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Modern technological approaches to ensuring the specific safety of human immunoglobulin and albumin preparations are analyzed. Introduction into human immunoglobulin preparation technology of donor screening for group- and rhesus-affiliations and chromatographic purification steps to reduce the contents of anti-A and anti-B hemagglutinins and anti-D antibodies are shown to be promising. Technological capabilities for reducing the anticomplementary activity and thrombogenic potential of immunoglobulin preparations and decreasing the contents of prekallikrein activator in human i.v. immunoglobulin and albumin preparations are discussed.

作者简介

O. Kornilova

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

M. Krivykh

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

É. Kudasheva

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

I. Borisevich

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018